Gyre Therapeutics Inc. (GYRE NASDAQ) stock market data APIs
$11.0358
-0.02(-0.2%)
as of May 19, 2025
Try our APIs with
free plan!
Gyre Therapeutics Inc. Financial Data Overview
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Prev. Close
11.0358
Open
11.0169
High
11.3008
Low
11.03
52 wk Range
6.11-19
Market Cap
979 M
P/E Ratio
555.5
Shares Outstanding
88 101 K
Revenue
101 M
EPS
-0.0011
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gyre Therapeutics Inc. data using free add-ons & libraries
Get Gyre Therapeutics Inc. Fundamental Data
Gyre Therapeutics Inc. Fundamental data includes:
- Net Revenue: 101 M
- EBITDA: 12 139 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-24
- EPS/Forecast: 0.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gyre Therapeutics Inc. News
New
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B (“CHB”)-associated l...
Discover the top movers in Monday's pre-market session.
Enable social media cookies to share Discover the top movers in Monday's pre-market session. By Mill Chart Last update: Apr 7, 2025 Before the opening bell on Monday, let's take a glimpse of the U...
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Gyre Therapeutics Inc. SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, to...
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings
The stock price didn't jump after Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted decent earnings last week. We did some digging and believe investors may be worried about some underlying factors in the ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
